[ad_1]
Oppenheimer thinks a key treatment for a range of autoimmune diseases can be a growth catalyst for Dianthus Therapeutics stock. The firm initiated coverage of the clinical stage biotechnology company with an outperform rating and a $48 per share price target in a Wednesday note. Oppenheimer’s forecast implies more than 71% upside from Wednesday’s $27.98 close. Shares have soared more than 169% in 2024. DNTH YTD mountain Dianthus Therapeutics stock. Analyst Trevor Allred attributed his rating to the potential for the company’s monoclonal antibody DNTH103 to treat a range of rare autoimmune conditions that include generalized myasthenia gravis, multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy. He estimates a more than $20 billion market for this treatment. “We see DNTH103 demonstrating potentially superior dosing/efficacy compared to on-market and late clinical-stage products in clinical trials, and anticipate data would support uptake in burgeoning markets across indications, led by the market expansion efforts of multiple pharma competitors,” Allred said. By 2035, the analyst said DNTH103 could tally $1 billion in sales when used to treat multifocal motor neuropathy, $2 billion for chronic inflammatory demyelinating polyneuropathy and $2.5 billion for generalized myasthenia gravis. Investors will be able to gain insight into the treatment’s effectiveness in clinical data that will begin to be released in mid-2025, Allred said.
[ad_2]
Source link
